EUVIMEDEUVIMED entdecken
Crossref

Risk of type 2 diabetes mellitus after treatment with direct-acting antivirals for Hepatitis C virus in people with HIV.

Mathieu Chalouni, Jessie Torgersen, Christopher T. Rentsch, Daniela K van Santen, Inmaculada Jarrín, Marina B. Klein, Jim Young, M John Gill, Rachel L. Epstein, Benjamin Paul Linas, Robert Zangerle, Bernard Surial und 14 weitere

Open Access CRIS of the University of Bern · 01.08.2026

DOI: 10.48620/96454 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Access CRIS of the University of Bern, erschienen am 01.08.2026. Verfasst von Mathieu Chalouni und 25 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To compare the 3-year risk of type 2 diabetes mellitus (T2DM) in people with HIV-HCV after direct-acting antiviral (DAA) initiation and in people with HIV mono-infection.

Design

An observational study of two collaborations of cohorts from Europe and North America.

Methods

We matched individuals with evidence of ongoing HIV-HCV co-infection eligible to receive DAA (HepCAUSAL Collaboration) with individuals with HIV mono-infection (HIV-CAUSAL Collaboration) on cohort, calendar month, and probability of HCV diagnosis. We estimated the 3-year post-DAA T2DM risk had all HIV-HCV co-infection individuals initiated DAA using inverse probability weighting and compared it with the risk people with HIV mono-infection in subgroups defined by number of diabetes risk factors (0, 1-2, or ≥3).

Results

34,135 people with HIV-HCV co-infection and 68,720 with HIV mono-infection were included. The difference in 3-year risk of T2DM for people with HIV-HCV after DAA and people with HIV mono-infection was 0.8% (95% confidence interval: -0.6, 5.8) in the subgroup with no risk factor, -0.4% (-1.5, 1.2) in the subgroup with 1-2 risk factors, and -1.7% (-4.7, 1.5) in the subgroup with ≥3 risk factors.

Conclusions

The estimated post-DAA risk of T2DM in people was similar to the risk in people with HIV mono-infection, though estimates were imprecise. These results suggest diabetes monitoring and prevention strategies should be the same for people with HIV who received DAA for HCV treatment as for people with HIV mono-infection, and based on risk factors.

Schlagwörter

type 2 diabetesdirect-acting antiviralshepatitis C virusHIV/HCV coinfectionHIV monoinfectiondiabetes risk factorsdiabetes preventiondiabetes monitoring

Zitieren

APA

Chalouni, M., Torgersen, J., Rentsch, C. T., Santen, D. K. V., Jarrín, I., Klein, M. B., Young, J., Gill, M. J., Epstein, R. L., Linas, B. P., Zangerle, R., Surial, B., Nemeth, J., Touloumi, G., Papadopoulos, A., Wittkop, L., Valk, M. V. D., Monforte, A. D., Boyd, A. C., …, & Lodi, S. (2026). Risk of type 2 diabetes mellitus after treatment with direct-acting antivirals for Hepatitis C virus in people with HIV. Open Access CRIS of the University of Bern. https://doi.org/10.48620/96454

Vancouver

Chalouni M, Torgersen J, Rentsch CT, Santen DKV, Jarrín I, Klein MB, et al. Risk of type 2 diabetes mellitus after treatment with direct-acting antivirals for Hepatitis C virus in people with HIV. Open Access CRIS of the University of Bern. 2026. doi:10.48620/96454

BibTeX
@article{Chalouni2026,
  author = {Chalouni, Mathieu and Torgersen, Jessie and Rentsch, Christopher T. and Santen, Daniela K van and Jarrín, Inmaculada and Klein, Marina B. and Young, Jim and Gill, M John and Epstein, Rachel L. and Linas, Benjamin Paul and Zangerle, Robert and Surial, Bernard and Nemeth, Johannes and Touloumi, Giota and Papadopoulos, Antonios and Wittkop, Linda and Valk, Marc van der and Monforte, Antonella D’arminio and Boyd, Anders C. and Puoti, Massimo and Logan, Roger W and Rein, Sophia M. and Miro, José M and Berenguer, Juan Berenguer and Hernán, Miguel Ángel and Lodi, Sara},
  title = {Risk of type 2 diabetes mellitus after treatment with direct-acting antivirals for Hepatitis C virus in people with HIV},
  journal = {Open Access CRIS of the University of Bern},
  year = {2026},
  doi = {10.48620/96454}
}
Kostenlos starten →